| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TOXLET.2003.07.005 |
| P698 | PubMed publication ID | 15068826 |
| P50 | author | Dallas Clouatre | Q122922418 |
| P433 | issue | 1 | |
| P304 | page(s) | 85-96 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Toxicology Letters | Q1796854 |
| P1476 | title | Kava kava: examining new reports of toxicity | |
| P478 | volume | 150 |
| Q43204898 | A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder |
| Q55279019 | A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications. |
| Q34558540 | Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides |
| Q47676260 | Adverse Effects of Nutraceuticals and Dietary Supplements |
| Q46304316 | An international pilot study of oncology physicians' opinions and practices on Complementary and Alternative Medicine (CAM). |
| Q28567320 | Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract |
| Q37879144 | Bioactivation of herbal constituents: simple alerts in the complex system. |
| Q36771550 | Current diagnosis and treatment of anxiety disorders |
| Q37802740 | Deleterious Effects of Reactive Metabolites |
| Q34449318 | Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice |
| Q37995233 | Diets, phytochemicals, and chemoprevention of tumorigenesis |
| Q38302838 | Drug-induced hepatotoxicity of select herbal therapies |
| Q37131844 | Effects of botanical dietary supplements on cardiovascular, cognitive, and metabolic function in males and females |
| Q46651133 | Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots |
| Q30396823 | Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources |
| Q55334671 | Evaluation of How Integrative Oncology Services Are Valued between Hematology/Oncology Patients and Hematologists/Oncologists at a Tertiary Care Center. |
| Q37730719 | Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements |
| Q34030746 | Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network |
| Q37554889 | Hepatotoxic herbs: will injury mechanisms guide treatment strategies? |
| Q37101690 | Hepatotoxic slimming aids and other herbal hepatotoxins. |
| Q26752375 | Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat |
| Q33621705 | Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence |
| Q42538565 | Herbal medicines and acute medical emergency admissions to hospital |
| Q33596382 | Herbs in hemato-oncological care: an evidence-based review of data on efficacy, safety, and drug interactions |
| Q46905469 | Identification of C-glycoside flavonoids as potential mutagenic compounds in kava |
| Q37375043 | Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity |
| Q28577347 | Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract |
| Q34419646 | In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes |
| Q44595110 | Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects. |
| Q37175348 | Kava, a tonic for relieving the irrational development of natural preventive agents |
| Q33745578 | Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology |
| Q51324784 | Kavalactone metabolism in rat liver microsomes. |
| Q38636806 | Management of side effects during and post-treatment in breast cancer survivors |
| Q34215362 | Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1. |
| Q35117223 | Natural product taking its own place!!! |
| Q33856072 | Neurocognitive effects of kava (Piper methysticum): a systematic review |
| Q53168100 | ORIGINAL ARTICLE: Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment |
| Q37468723 | Quality assurance and safety of herbal dietary supplements. |
| Q34464495 | Safety issues associated with herbal ingredients |
| Q64069168 | Species: A Comprehensive Review on Their Phytochemistry, Biological Activities and Applications |
| Q34607485 | The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum |
| Q38154682 | The flavokawains: uprising medicinal chalcones |
| Q34554574 | The use of selected nutrition supplements and complementary and alternative medicine in liver disease |
| Q34759111 | Toxicity of kava kava |
| Q41763713 | Toxicokinetics of kava |
| Q33583404 | Use of complementary and alternative medicine in a large sample of anxiety patients |
| Q62630887 | What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, ‘legal highs’)? Implications for law enforcement and penalties |
Search more.